A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
Public ClinicalTrials.gov record NCT03631784. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab monotherapy. The primary hypothesis of the trial is that within each platinum doublet chemotherapy cohort, the percentage of participants who develop Grade 3 or higher pneumonitis is ≤10% and estimation of objective response rate (ORR) by blinded independent central review (BICR).
Study identification
- NCT ID
- NCT03631784
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 216 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab 200 mg Drug
- Paclitaxel 45 mg/m^2 Drug
- Carboplatin AUC6 Drug
- Cisplatin 75 mg/m^2 Drug
- Pemetrexed 500 mg/m^2 Drug
- Thoracic Radiation Therapy (TRT) Radiation
- Paclitaxel 200 mg/m^2 Drug
- Carboplatin AUC2 Drug
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 19, 2018 (Actual)
- Primary completion
- Oct 18, 2021 (Actual)
- Completion
- Mar 19, 2024 (Actual)
- Last update posted
- Mar 25, 2025
2018 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St Joseph Heritage Healthcare ( Site 1403) | Santa Rosa | California | 95403 | — |
| North Shore University Health System ( Site 1413) | Evanston | Illinois | 60201 | — |
| Parkview Cancer Institute ( Site 1415) | Fort Wayne | Indiana | 46845 | — |
| UMass Memorial Medical Center ( Site 1417) | Worcester | Massachusetts | 01655 | — |
| Henry Ford Hospital ( Site 1418) | Detroit | Michigan | 48202 | — |
| St. Francis Cancer Treatment Center ( Site 1421) | Grand Island | Nebraska | 68803 | — |
| Rutgers Cancer Institute of New Jersey ( Site 1422) | New Brunswick | New Jersey | 08903 | — |
| CTCA Southwestern ( Site 1428) | Tulsa | Oklahoma | 74133 | — |
| Fox Chase Cancer Center ( Site 1433) | Philadelphia | Pennsylvania | 19111 | — |
| Sanford Cancer Center Oncology Clinic ( Site 1434) | Sioux Falls | South Dakota | 57104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03631784, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 25, 2025 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03631784 live on ClinicalTrials.gov.